乙型肝炎病毒再激活及其预防性治疗

doi:10.3877/cma.j.issn.1674-1358.2017.01.002

全球约20亿人曾感染乙型肝炎病毒（HBV），而任何损害免疫应答的因素均可能明显改变HBV感染的状态，引发HBV感染再激活。再激活可表现为无症状，也可为暴发性肝炎、肝功能衰竭甚至死亡。在不同危险因素下，HBV再激活率为24%～88%，病死率高于10%。HBV再激活的危险因素包括使用生物制剂、糖皮质激素，基线高病毒载量以及HBV表面抗原阳性等。准备接受化疗和免疫抑制剂治疗的患者均需进行HBV标志物筛查，并进行危险度分级，继而确定预防性治疗方案，这对预防HBV再激活所致的危害具有重要意义。

关键词: 肝炎病毒, 乙型, 再激活, 预防

It is estimated that two billion people have had hepatitis B virus (HBV) infection worldwide. Any immunocompromised status will change the state of HBV infection and lead to HBV reactivation. The consequences of reactivation could be asymptomatic, fulminant hepatitis, hepatic failure and even death. The reactivation rate of HBV ranges from 24% to 88% with different risk factors, and the mortality rate is higher than 10%. The risk factors include the use of biological agents and glucocorticoids, high level of viral load at baseline, and positive HBV surface antigen, etc. All candidates for chemotherapy and immunosuppressive therapy should be screened for HBV infection, and receive risk classification and then prevention and treatment, which is significant for preventing the hazard that caused by HBV reactivation.

Key words: Hepatitis B virus, Reactivation, Prophylaxis

表1 HBV再激活危险度分层

影响因素	预测HBV再激活率	HBsAg	HBcAb	糖皮质激素	其他药物
高危因素	> 10%	+	+	/	B细胞单克隆抗^a
		-	+	/	B细胞单克隆抗体
		+	+	/	蒽环类衍生物^b
		+	+	每日中等剂量^c或大剂量^d疗程≥ 4周	/
中危因素	1%～10%	+	+	/	抗TNFα^e，细胞因子单克隆抗体^f，酪氨酸激酶抑制剂^g
		-	+	/	抗TNFα，细胞因子单克隆抗体，酪氨酸激酶抑制剂，蒽环类衍生物
		+	+	每日小剂量^h疗程≥ 4周	/
		-	+	每日中等剂量或大剂量疗程≥ 4周	/
低危因素	< 1%	+	+	/	硫唑嘌呤，甲氨蝶呤，关节内糖皮质激素治疗
		-	+	/	硫唑嘌呤，甲氨蝶呤
		+	+	任意剂量疗程≤ 1周	/
		-	+	任意剂量疗程≤ 1周	/
		+	+	小剂量疗程≥ 4周	/

表1 HBV再激活危险度分层

影响因素	预测HBV再激活率	HBsAg	HBcAb	糖皮质激素	其他药物
高危因素	> 10%	+	+	/	B细胞单克隆抗^a
		-	+	/	B细胞单克隆抗体
		+	+	/	蒽环类衍生物^b
		+	+	每日中等剂量^c或大剂量^d疗程≥ 4周	/
中危因素	1%～10%	+	+	/	抗TNFα^e，细胞因子单克隆抗体^f，酪氨酸激酶抑制剂^g
		-	+	/	抗TNFα，细胞因子单克隆抗体，酪氨酸激酶抑制剂，蒽环类衍生物
		+	+	每日小剂量^h疗程≥ 4周	/
		-	+	每日中等剂量或大剂量疗程≥ 4周	/
低危因素	< 1%	+	+	/	硫唑嘌呤，甲氨蝶呤，关节内糖皮质激素治疗
		-	+	/	硫唑嘌呤，甲氨蝶呤
		+	+	任意剂量疗程≤ 1周	/
		-	+	任意剂量疗程≤ 1周	/
		+	+	小剂量疗程≥ 4周	/

表2 各国指南对乙型肝炎病毒再激活的预防策略

指南	筛查人群	筛查项目	预防用药疗程	药物选择	疫苗
中国慢乙型肝炎指南2015版^[41]	所有准备接受化疗及免疫治疗的患者	HBsAg、HBcAb、HBV DNA	治疗前1周至停止治疗后6个月	恩替卡韦或替诺福韦酯	/
AASLD2009版^[42]	高危人群	HBsAg、HBcAb	HBV DNA<2 000 U/ml，停止治疗后6个月；HBV DNA >2 000 U/ml，同慢性乙型肝炎患者的治疗终点	预期治疗持续时间较短（≤ 12个月）且，血清HBV DNA低于检测下限，拉米夫定或替比夫定；预期治疗持续时间较长，则优选恩替卡韦或替诺福韦酯	/
EASL2012版^[40]	所有准备接受化疗及免疫治疗的患者	HBsAg、HBcAb；必要时检测HBV DNA	停止治疗后12个月	预期治疗持续时间较短，HBV DNA< 2 000 U/ml，拉米夫定；预期治疗持续时间较长，HBV DNA> 2 000 U/ml，选择恩替卡韦和替诺福韦酯	血清学阴性时
AGA2015版^[9]	中高危人群	HBsAg、HBcAb；必要时检测HBV DNA	停止治疗后6个月；B细胞单克隆抗体最少12个月	建议采用更不易产生耐药性的药物	/
APASL2015版^[43]	所有准备接受化疗及免疫治疗的患者	HBsAg、HBcAb；必要时检测HBV DNA	停止治疗后12个月	/	HBsAb阴性时

表2 各国指南对乙型肝炎病毒再激活的预防策略

指南	筛查人群	筛查项目	预防用药疗程	药物选择	疫苗
中国慢乙型肝炎指南2015版^[41]	所有准备接受化疗及免疫治疗的患者	HBsAg、HBcAb、HBV DNA	治疗前1周至停止治疗后6个月	恩替卡韦或替诺福韦酯	/
AASLD2009版^[42]	高危人群	HBsAg、HBcAb	HBV DNA<2 000 U/ml，停止治疗后6个月；HBV DNA >2 000 U/ml，同慢性乙型肝炎患者的治疗终点	预期治疗持续时间较短（≤ 12个月）且，血清HBV DNA低于检测下限，拉米夫定或替比夫定；预期治疗持续时间较长，则优选恩替卡韦或替诺福韦酯	/
EASL2012版^[40]	所有准备接受化疗及免疫治疗的患者	HBsAg、HBcAb；必要时检测HBV DNA	停止治疗后12个月	预期治疗持续时间较短，HBV DNA< 2 000 U/ml，拉米夫定；预期治疗持续时间较长，HBV DNA> 2 000 U/ml，选择恩替卡韦和替诺福韦酯	血清学阴性时
AGA2015版^[9]	中高危人群	HBsAg、HBcAb；必要时检测HBV DNA	停止治疗后6个月；B细胞单克隆抗体最少12个月	建议采用更不易产生耐药性的药物	/
APASL2015版^[43]	所有准备接受化疗及免疫治疗的患者	HBsAg、HBcAb；必要时检测HBV DNA	停止治疗后12个月	/	HBsAb阴性时

1	Ott JJ, Stevens GA, Groeger J, et al. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity[J]. Vaccine,2012,30(12):2212-2219.
2	Hoofnagle JH. Reactivation of hepatitis B[J]. Hepatology,2009,49(Suppl 5):S156-S165.
3	Loomba R, Rowley A, Wesley R, et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy[J]. Ann Intern Med,2008,148(7):519-528.
4	Hwang JP, Lok ASF. Management of patients with hepatitis B who require immunosuppressive therapy[J]. Nature Reviews Gastroenterology & Hepatology Nat Rev Gastroenterol Hepatol,2013,11(4):209-219.
5	Jang JW, Choi JY, Bae SH, et al. A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization[J]. Hepatology,2006,43(2):233-240.
6	Saab S, Dong MH, Joseph TA, et al. Hepatitis B prophylaxis in patients undergoing chemotherapy for lymphoma: a decision analysis model[J]. Hepatology,2007,46(4):1049-1056.
7	Loras C, Gisbert JP, Minguez M, et al. Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy[J]. Gut,2010,59(10):1340-1346.
8	Perez-Alvarez R, Diaz-Lagares C, Garcia-Hernandez F, et al. Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases[J]. Medicine (Baltimore),2011,90(6):359-371.
9	Reddy KR, Beavers KL, Hammond SP, et al. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy[J]. Gastroenterology,2015,148(1):215-219, e16-e17.
10	Seto WK, Chan TS, Hwang YY, et al. Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study[J]. J Clin Oncol,2014,32(33):3736-3743.
11	Kim SJ, Hsu C, Song YQ, et al. Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: analysis from the Asia Lymphoma Study Group[J]. Eur J Cancer,2013,49(16):3486-3496.
12	Dong HJ, Ni LN, Sheng GF, et al. Risk of hepatitis B virus (HBV) reactivation in non-Hodgkin lymphoma patients receiving rituximab-chemotherapy: a meta-analysis[J]. J Clin Virol,2013,57(3):209-214.
13	Yeo W, Chan TC, Leung NW, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab[J]. J Clin Oncol,2009,27(4):605-611.
14	Navarro R, Vilarrasa E, Herranz P, et al. Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical setting[J]. Br J Dermatol,2013,168(3):609-616.
15	Ryu HH, Lee EY, Shin K, et al. Hepatitis B virus reactivation in rheumatoid arthritis and ankylosing spondylitis patients treated with anti-TNF-alpha agents: a retrospective analysis of 49 cases[J]. Clin Rheumatol,2012,31(6):931-936.
16	Kim PS, Ho GY, Prete PE, et al. Safety and efficacy of abatacept in eight rheumatoid arthritis patients with chronic hepatitis B[J]. Arthritis Care Res (Hoboken),2012,64(8):1265-1268.
17	Lee YH, Bae SC, Song GG. Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapy[J]. Clin Exp Rheumatol,2013,31(1):118-121.
18	Chyuan IT, Tsai HF, Tzeng HT, et al. Tumor necrosis factor-alpha blockage therapy impairs hepatitis B viral clearance and enhances T-cell exhaustion in a mouse model[J]. Cell Mol Immunol,2015,12(3):317-325.
19	Kim SY, Solomon DH. Tumor necrosis factor blockade and the risk of viral infection[J]. Nat Rev Rheumatol,2010,6(3):165-174.
20	Okuyama-Dobashi K, Kasai H, Tanaka T, et al. Hepatitis B virus efficiently infects non-adherent hepatoma cells via human sodium taurocholate cotransporting polypeptide[J]. Sci Rep,2015,5:17047.
21	Chou CK, Wang LH, Lin HM, et al. Glucocorticoid stimulates hepatitis B viral gene expression in cultured human hepatoma cells[J]. Hepatology,1992,16(1):13-18.
22	Tur-Kaspa R, Burk RD, Shaul Y, et al. Hepatitis B virus DNA contains a glucocorticoid-responsive element[J]. Proc Natl Acad Sci USA,1986,83(6):1627-1631.
23	Tur-Kaspa R, Shaul Y, Moore DD, et al. The glucocorticoid receptor recognizes a specific nucleotide sequence in hepatitis B virus DNA causing increased activity of the HBV enhancer[J]. Virology,1988,167(2):630-633.
24	Cheng A. Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma[J]. Hepatology,2003,37(6):1320-1328.
25	中华医学会血液学分会，中国抗癌协会淋巴瘤专业委员会，中华医学会肝病学分会. 中国淋巴瘤合并HBV感染患者管理专家共识[J]. 中华血液学杂志,2013,34(11):988-993.
26	Hsu CH, Hsu HC, Chen HL, et al. Doxorubicin activates hepatitis B virus (HBV) replication in HBV-harboring hepatoblastoma cells. A possible novel mechanism of HBV reactivation in HBV carriers receiving systemic chemotherapy[J]. Anticancer Res,2004,24(5A):3035-3040.
27	Liang RH, Lok AS, Lai CL, et al. Hepatitis B infection in patients with lymphomas[J]. Hematol Oncol,1990,8(5):261-270.
28	Hsiao LT, Chiou TJ, Gau JP, et al. Risk of reverse seroconversion of hepatitis B virus surface antigen in rituximab-treated non-hodgkin lymphoma patients: a large cohort retrospective study[J]. Medicine (Baltimore),2015,94(32):e1321.
29	Yeo W, Zee B, Zhong S, et al. Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy[J]. Br J Cancer,2004,90(7):1306-1311.
30	Yeo W, Chan PK, Hui P, et al. Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study[J]. J Med Virol,2003,70(4):553-561.
31	Yun J, Kim KH, Kang ES, et al. Prophylactic use of lamivudine for hepatitis B exacerbation in post-operative breast cancer patients receiving anthracycline-based adjuvant chemotherapy[J]. Br J Cancer,2011,104(4):559-563.
32	Chan TM, Fang GX, Tang CS, et al. Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients[J]. Hepatology,2002,36(5):1246-1252.
33	Chen GD, Gu JL, Qiu J, et al. Outcomes and risk factors for hepatitis B virus (HBV) reactivation after kidney transplantation in occult HBV carriers[J]. Transpl Infect Dis,2013,15(3):300-305.
34	Lau GK, Yiu HH, Fong DY, et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy[J]. Gastroenterology,2003,125(6):1742-1749.
35	Hammond SP, Borchelt AM, Ukomadu C, et al. Hepatitis B Virus Reactivation following Allogeneic Hematopoietic Stem Cell Transplantation[J]. Biol Blood Marrow Transplant 2009,15(9):1049-1059.
36	Visram A, Chan KK, Mcgee P, et al. Poor recognition of risk factors for hepatitis B by physicians prescribing immunosuppressive therapy: a call for universal rather than risk-based screening[J]. PLoS One,2015,10(4):e120749.
37	Hwang JP, Fisch MJ, Zhang H, et al. Low rates of hepatitis B virus screening at the onset of chemotherapy[J]. J Oncol Pract,2012,8(4):e32-e39.
38	Kohrt HE, Ouyang DL, Keeffe EB. Systematic review: lamivudine prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection[J]. Aliment Pharmacol Ther,2006,24(7):1003-1016.
39	Paul S, Saxena A, Terrin N, et al. Hepatitis B Virus Reactivation and Prophylaxis During Solid Tumor Chemotherapy: A Systematic Review and Meta-analysis[J]. Ann Intern Med,2016,164(1):30-40.
40	EASL Clinical Practice Guidelines: Management of chronic hepatitis B[J]. J Hepatol,2009,50(2):227-242.
41	中华医学会肝病学分会，中华医学会感染病学分会. 慢性乙型肝炎防治指南(2015年更新版)[J]. 临床肝胆病杂志,2015,31(12):1941-1960.
42	Lok AS, Mcmahon BJ. Chronic hepatitis B: update 2009[J]. Hepatology,2009,50(3):661-662.
43	Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update[J]. Hepatol Int,2016,10(1):1-98.
44	Chen WC, Cheng JS, Chiang PH, et al. A Comparison of entecavir and lamivudine for the prophylaxis of hepatitis B virus reactivation in solid tumor patients undergoing systemic cytotoxic chemotherapy[J]. PLoS One,2015,10(6):e131545.
45	Hwang JP, Lok AS. Management of patients with hepatitis B who require immunosuppressive therapy[J]. Nat Rev Gastroenterol Hepatol,2014,11(4):209-219.
46	Tenney DJ, Rose RE, Baldick CJ, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy[J]. Hepatology,2009,49(5):1503-1514.
47	Cooper RD, Wiebe N, Smith N, et al. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients[J]. Clin Infect Dis,2010,51(5):496-505.
48	Huang H, Li X, Zhu J, et al. Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial[J]. JAMA,2014,312(23):2521-2530.
49	Perrillo RP, Gish R, Falck-Ytter YT. American Gastroenterological Association Institute Technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy[J]. Gastroenterology,2015,148(1):221-244.

[1]	卢天祺, 张巍, 周康, 毕士玉, 张羽, 杨秀华. 血流向量成像技术在不同Child-Pugh分级乙肝患者左心功能评价中的价值[J/OL]. 中华医学超声杂志（电子版）, 2024, 21(04): 352-360.
[2]	刘莉莉, 贾建茹, 张晶, 周大琼, 刘江雨, 曹振环. 单纯慢性乙型肝炎患者与慢性乙型肝炎合并肝脂肪变患者的临床特征横断面研究[J/OL]. 中华实验和临床感染病杂志(电子版), 2024, 18(05): 270-277.
[3]	江志鹏, 钟克力, 陈双. 复杂腹壁疝手术后腹腔高压与腹腔间室综合征的预防和处理[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(06): 612-615.
[4]	王学虎, 赵渝. 复杂腹壁疝手术中血管损伤并发症的预防和处理[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(06): 616-619.
[5]	林凯, 潘勇, 赵高平, 杨春. 造口还纳术后切口疝的危险因素分析与预防策略[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(06): 634-638.
[6]	李干斌, 侯睿, 郭雅萍, 张潇, 邱小原, 牛备战, 林国乐. 改良经辅助切口回肠造口在腹腔镜直肠癌根治术的应用[J/OL]. 中华腔镜外科杂志(电子版), 2024, 17(05): 271-276.
[7]	刘敏思, 李荣, 李媚. 基于GGT与Plt比值的模型在HBV相关肝细胞癌诊断中的作用[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 831-835.
[8]	邓万玉, 陈富, 许磊波. 肝硬化与非肝硬化乙肝相关性肝癌患者术后无复发生存比较及其影响因素分析[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 670-674.
[9]	周璐, 温镕博, 刘子璇, 李奕飏, 周乐其, 朱晓明, 龚海峰, 高显华, 楼征, 刘连杰, 郝立强, 于冠宇, 张卫. Changhai-AL-Prediction预测模型指导预防性造口合理实施的卫生经济学研究[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(04): 280-287.
[10]	李佳曦, 刘子源, 李学民. 二甲双胍对年龄相关性白内障影响的研究进展[J/OL]. 中华眼科医学杂志(电子版), 2024, 14(04): 252-256.
[11]	董佳, 王坤, 张莉. 预后营养指数结合免疫球蛋白、血糖及甲胎蛋白对HBV 相关慢加急性肝衰竭患者治疗后预后不良的预测价值[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 555-559.
[12]	胡静, 杨秀锦, 侯志云. HBV感染患者外周血ISGs表达水平变化及其与干扰素治疗疗效的关系[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(04): 343-347.
[13]	黄圣楷, 许斌, 苏健, 孙龙. 海南省2010~2020年乙型肝炎流行趋势的时间序列分析及预测[J/OL]. 中华临床医师杂志(电子版), 2024, 18(06): 555-561.
[14]	陈芳, 王建英, 曹建用, 刘丽, 罗晓琴. 基于分析-设计-开发-实施-评价模式的叙事护理培训在产科预防性介入治疗中的应用[J/OL]. 中华介入放射学电子杂志, 2024, 12(04): 392-396.
[15]	李兰兰, 龚忆华, 陈泳欣, 郑纯翠, 易石坚. 失效模式和效果分析模式提高医院保洁人员标准预防依从性的效果[J/OL]. 中华卫生应急电子杂志, 2024, 10(05): 277-280.

阅读次数

全文

摘要

选择文件类型/文献管理软件名称

选择包含的内容

Hepatitis B virus reactivation and prophylaxis

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

Hepatitis B virus reactivation and prophylaxis